Multi-Functional MPT Protein as a Therapeutic Agent against Mycobacterium tuberculosis

Area of Science:

• Immunology
• Microbiology
• Vaccinology

Background:

• Mycobacterium tuberculosis (MTB), the cause of tuberculosis (TB), employs virulence factors like MPT63 and MPT64 to evade host immunity.
• These factors manipulate host proteins, facilitating MTB survival and proliferation within the host.
• Understanding these interactions is crucial for developing novel anti-TB strategies.

Purpose of the Study:

• To investigate the interactions of MTB virulence factors MPT63 and MPT64 with host immune proteins.
• To construct and evaluate a multifunctional recombinant protein (rMPT) derived from MPT63/64 as a potential anti-TB agent.
• To assess the efficacy of rMPT in modulating immune responses and combating MTB infection in vitro and in vivo.

Main Methods:

• Identified direct binding partners of MPT63 (TBK1, p47phox) and MPT64 (TBK1, HK2).
• Engineered a recombinant protein, rMPT, designed to interact with these identified host targets.
• Evaluated rMPT's effects on immune signaling (IFN-β), inflammation, reactive oxygen species (ROS) production, and MTB killing in cellular and animal models, including vaccination studies.

Main Results:

• MPT63 binds TBK1 and p47phox; MPT64 binds TBK1 and HK2.
• The constructed rMPT interacts with TBK1, p47phox, and HK2.
• rMPT treatment modulated IFN-β levels, increased inflammation and ROS, targeted macrophages, and demonstrated in vitro and in vivo killing of MTB, with positive outcomes in a mouse vaccination model.

Conclusions:

• The multifunctional recombinant protein rMPT effectively interacts with key host immune signaling components targeted by MTB virulence factors.
• rMPT demonstrates significant potential as a vaccine or therapeutic agent against Mycobacterium tuberculosis by modulating immune responses and directly combating the pathogen.
• Further development of rMPT could lead to novel strategies for controlling tuberculosis.